Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAT2A | P31153 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26126788 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL30608069 | 0.87 | MAPK8 (0.49) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL26125920 | 0.87 | MAPK8 (0.49) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL13384795 | 0.83 | KDM4E (0.46) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL30608067 | 0.82 | HPGD (0.54) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL26125404 | 0.82 | HPGD (0.54) | ALDH1A1KDM4ENPSR1MAT2AHPGD | |
| SCHEMBL30549013 | 0.81 | MAT2A (0.57) | ALDH1A1MAT2ACYP1A2 | |
| SCHEMBL29091374 | 0.81 | MAT2A (0.57) | ALDH1A1MAT2ACYP1A2 | |
| SCHEMBL24123109 | 0.78 | MAT2A (0.43) | ALDH1A1KDM4ENPSR1MAT2ARXFP1 | |
| SCHEMBL13384742 | 0.77 | MAT2A (0.40) | ALDH1A1KDM4ENPSR1MAT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116924983-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | ALDH1A1 996/4885KDM4E 3698/4885NPSR1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.